Q-omics provides the consensus-scored ZC3H18 profile across patient tissues and cancer cell-line models. ZC3H18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZC3H18 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, ZC3H18 protein abundance shows 29,305 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, KIRP, and GBM as cancer lineages where ZC3H18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H18 survival associations across molecular data types. ZC3H18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H18 RNA expression–survival associations across cancer types. High ZC3H18 expression shows unfavorable associations in LIHC, ACC and MESO, but favorable associations in SCLC, KIRC and THYM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ZC3H18 RNA expression.
This table summarizes ZC3H18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZC3H18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H18 shows higher tumor expression in KIRP, HNSC, COAD, KIRC, LIHC and BLCA. The KIRP box plot shows higher ZC3H18 RNA expression in tumor versus normal tissue (log2 FC = +1.410, t-test p < 0.001).
This table shows molecular features associated with ZC3H18 in patient tissues and cancer cell lines. In patient samples, ZC3H18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
